The SARS-CoV-2-specific antibodies in humans are likely to be produced in response to vaccination or infection, but an important difference between the two is that during virus infections, the main infection sites receive long-term high levels of stimulation, which induces strong mucosal immune responses and is reflected in the rise in IgA levels. This evidence concerns the gene CD79A and viral infectious disease.